Efficacy and safety of the combination of docetaxel (Taxotere®) with targeted therapies in the treatment of solid malignancies

Vincenzo Emanuele Chiuri, Nicola Silvestris, Andrea Tinelli, Vito Lorusso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

Original languageEnglish
Pages (from-to)982-1000
Number of pages19
JournalCurrent Drug Targets
Volume10
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

docetaxel
Safety
Pharmaceutical Preparations
Tumors
Neoplasms
Appointments and Schedules
Cells
Maintenance
Clinical Trials
Phenotype
Therapeutics

Keywords

  • BCL-2
  • Docetaxel
  • Efficacy
  • EGFR
  • PDGFR
  • RTKI
  • Safety
  • Solid tumors
  • Targeted therapy
  • VEGFR

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Efficacy and safety of the combination of docetaxel (Taxotere®) with targeted therapies in the treatment of solid malignancies. / Chiuri, Vincenzo Emanuele; Silvestris, Nicola; Tinelli, Andrea; Lorusso, Vito.

In: Current Drug Targets, Vol. 10, No. 10, 2009, p. 982-1000.

Research output: Contribution to journalArticle

@article{4b6939b099f44dd2b0411e2aa2579957,
title = "Efficacy and safety of the combination of docetaxel (Taxotere{\circledR}) with targeted therapies in the treatment of solid malignancies",
abstract = "Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.",
keywords = "BCL-2, Docetaxel, Efficacy, EGFR, PDGFR, RTKI, Safety, Solid tumors, Targeted therapy, VEGFR",
author = "Chiuri, {Vincenzo Emanuele} and Nicola Silvestris and Andrea Tinelli and Vito Lorusso",
year = "2009",
doi = "10.2174/138945009789578007",
language = "English",
volume = "10",
pages = "982--1000",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Efficacy and safety of the combination of docetaxel (Taxotere®) with targeted therapies in the treatment of solid malignancies

AU - Chiuri, Vincenzo Emanuele

AU - Silvestris, Nicola

AU - Tinelli, Andrea

AU - Lorusso, Vito

PY - 2009

Y1 - 2009

N2 - Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

AB - Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

KW - BCL-2

KW - Docetaxel

KW - Efficacy

KW - EGFR

KW - PDGFR

KW - RTKI

KW - Safety

KW - Solid tumors

KW - Targeted therapy

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=70450209025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450209025&partnerID=8YFLogxK

U2 - 10.2174/138945009789578007

DO - 10.2174/138945009789578007

M3 - Article

VL - 10

SP - 982

EP - 1000

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -